ClinicalTrials.gg
RecruitingNCT07310862VR-GSSUpdated Oct 22, 2026

Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis

An interventional study of Virtual Reality Gamma Sensory Stimulation and Virtual Reality Sham Sensory Stimulation in Multiple Sclerosis, sponsored by Clarity Health Technologies, Inc. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Clarity Health Technologies, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.

Planned enrollment
158th of 202
30 · median 137
Started
2026
with 11 others
No phase
68 of 230
22 open now
Primary completion
2027-06
later than 35 of 55 live
Registered
216th of 230
by date

Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 158th largest by planned enrollment of the 202 interventional ones that give a count, is one of 12 that started in 2026, is one of 68 with no phase, reaches primary completion later than 35 of the 55 other live ones, and was the 216th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Multiple Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

This is a double-blind, parallel, randomized, sham-controlled pilot study evaluating the safety, feasibility, and efficacy of Gamma Sensory Stimulation (GSS) delivered via a Virtual Reality (VR) headset in individuals with Multiple Sclerosis (MS) who experience moderate to severe fatigue. Participants will be randomized (1:1) to 4 weeks of active GSS or sham stimulation, followed by a 4-week post-treatment follow-up. The primary objective is to determine whether GSS reduces fatigue, measured by the Modified Fatigue Impact Scale (MFIS). Secondary outcomes include additional fatigue scales, cognitive performance, quality-of-life measures, tolerability and safety.

Read the detailed description

Gamma Sensory Stimulation (GSS) is a non-invasive audiovisual neuromodulation method that delivers synchronized 40 Hz stimulation to engage gamma-band neural oscillations. Gamma-frequency activity is implicated in cognitive processing and large-scale network coordination, which may be disrupted in people with Multiple Sclerosis (MS), particularly in those experiencing fatigue. Prior research suggests that gamma-frequency entrainment may modulate neural network activity and support functional outcomes.

This single-center, double-blind, randomized, sham-controlled pilot study investigates whether 4 weeks of GSS delivered through an immersive Virtual Reality (VR) system can reduce fatigue in individuals with MS. Participants with moderate to severe fatigue will be randomized in a 1:1 ratio to receive either active GSS or sham stimulation embedded in matched VR content. The intervention consists of 16 in-lab stimulation sessions delivered over 4 weeks (4 sessions per week). Each session includes 30 minutes of active stimulation within a standardized VR experience.

The primary endpoint is the change in Modified Fatigue Impact Scale (MFIS) total score from baseline to End of Treatment (Week 4). Secondary endpoints include changes from baseline to End of Treatment (Week 4) and follow-up (Week 8) in additional validated fatigue measures (Fatigue Severity Scale, Visual Analogue Scale for Mental Fatigue, PROMIS Fatigue), cognitive performance assessed by the Symbol Digit Modalities Test (SDMT), quality-of-life measures (Neuro-QoL Fatigue), and the rate of change in Daily Fatigue Severity (DFS) across the treatment period. Exploratory outcomes include MFIS subscale scores, variability in daily fatigue ratings, embedded cognitive task performance during stimulation, and treatment acceptability.

Safety and tolerability will be assessed through monitoring of adverse events, session attendance, and retention. Electroencephalography (EEG) will be collected at baseline and at End of Treatment (Week 4) for exploratory characterization of neural responses to gamma-frequency stimulation.

This pilot investigation aims to generate preliminary safety, feasibility, and efficacy data to inform future multisite studies evaluating VR-based GSS as a potential at-home therapeutic approach for MS-related fatigue.

03

Conditions studied

  • Multiple Sclerosis

Keywords

  • Fatigue
  • MS fatigue
  • Cognitive Fatigue
  • Mental Fatigue
  • GSS
  • Gamma Sensory Stimulation
  • VR-GSS
  • Virtual Reality
  • MFIS
  • Neuromodulation
  • 40Hz
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be between 18 to 65 years of age (inclusive) on the day of signing .
  2. Have MS (McDonald criteria 2017) with Modified Fatigue Impact Scale (MFIS) score greater than 33 OR fatigue greater than 4 (out of 7) on the Fatigue Severity Scale (FSS).
  3. Sufficient hearing and vision.
  4. Any type of disease modifying therapy is allowed and should be stable in the last 3 months.
  5. Not having received the previous month.
  6. Each subject must sign the informed consent form, in accordance with local requirements, after the scope and nature of the investigation have been explained to the subject, and before Screening assessments.
  7. Based on the investigator's judgment, the subject should:

    1. Be able to speak, read, and understand the language of the trial staff and the informed consent form;
    2. Possess the ability to respond verbally to questions, follow instructions, and complete study assessments;
    3. Be able to adhere to the stimulation protocol and visit schedules.
  8. Women of * must have a negative urine pregnancy test before the inclusion in the study and agree to use highly effective methods during the study. Highly effective contraceptive methods will include intrauterine device, implant, patch or pill, bilateral tubal occlusion, vasectomized partner and sexual abstinence.

Exclusion criteria

Exclusion Criteria:

  1. Any condition or therapy impairing trial participation and assessments.
  2. The presence of a relapse or use of IV for any reason 3 months prior to screening visit.
  3. Severe systemic diseases or history of cancer or hereditary familiar cancer.
  4. concomitant disease: cardiac, gastrointestinal, hepatic, pulmonary, neurological, renal or other major disease.
  5. A history of seizure or epilepsy.
  6. Pregnant or breastfeeding women.
  7. Drug or alcohol abuse.
  8. Patients with active systemic bacterial, viral or fungal infections, or known to have uncontrolled AIDS or to be -positive but not receiving anti-retroviral therapy based on medical history or available clinical information at screening.
  9. Dementia or severe psychiatric, cognitive or behavioral problems or other comorbidity that may interfere with the compliance to the protocol.
  10. Any other clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the subject at risk by participating in the study.
  11. Participation in other experimental studies within the previous 90 days prior to screening visit.
  12. Patients having a pacemaker or other metal implants.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Gamma Sensory Stimulation

    Participants receive Gamma Sensory Stimulation delivered through a virtual reality (VR) headset and headphones. Stimulation sessions last 30 minutes and are delivered four times per week for four weeks within standardized, engaging VR environments.

    Device: Virtual Reality Gamma Sensory Stimulation

  • Sham comparator
    Sham Sensory Stimulation

    Participants receive sham sensory stimulation delivered through a virtual reality (VR) headset and headphones. Sessions last 30 minutes and are delivered four times per week for four weeks within the same VR environments used in the active intervention.

    Device: Virtual Reality Sham Sensory Stimulation

Interventions

  • DeviceVirtual Reality Gamma Sensory Stimulation

    Participants receive 30 minutes of Gamma Sensory Stimulation delivered through a virtual reality (VR) headset and headphones. Visual and auditory stimulation parameters are configured to deliver rhythmic sensory stimulation intended to engage gamma-band neural activity. Sessions occur four times per week for four weeks and are embedded within standardized VR environments.

    Also known as: 40 Hz sensory stimulation, 40 Hz audiovisual stimulation, Gamma flickers, 40Hz flickers, VR-GSS

  • DeviceVirtual Reality Sham Sensory Stimulation

    Participants receive 30 minutes of sham sensory stimulation delivered through a virtual reality (VR) headset and headphones. The sham intervention uses identical VR environments, session duration, and procedures as the active intervention, providing an equivalent participant experience without delivering therapeutic stimulation. Sessions occur four times per week for four weeks.

    Also known as: sham sensory stimulation, sham VR-GSS

06

What researchers measure

Primary outcomes

  1. Change in Modified Fatigue Impact Scale (MFIS) total score

    The Modified Fatigue Impact Scale (MFIS) is a 21-item patient-reported outcome assessing the impact of fatigue on physical, cognitive, and psychosocial functioning. Scores range from 0 to 84, with higher scores indicating greater fatigue impact. This outcome measures the change in MFIS total score from baseline to Week 4. Negative change values represent improvement in fatigue.

    Time frame: Baseline to End of Treatment (week 4)

Secondary outcomes

  1. Change in MFIS at Follow up

    MFIS is a 21-item patient-reported fatigue impact scale (range 0-84; higher scores indicate greater fatigue). This outcome assesses change in total MFIS score from baseline to follow-up assessment (Week 8).

    Time frame: Baseline to Follow-up (week 8)

  2. Change in Fatigue Severity Scale (FSS)

    The Fatigue Severity Scale (FSS) is a 9-item questionnaire assessing the severity and functional impact of fatigue on daily activities. Each item is scored 1-7; the final score is the mean of all items, with higher scores indicating more severe fatigue. This outcome reflects change in FSS score from baseline to Week 4 and Week 8.

    Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)

  3. Change in Visual Analogue Scale for Mental Fatigue (VAS-MF)

    VAS-MF is a single-item 0-100 mm visual analogue scale measuring perceived mental fatigue. Higher values indicate greater fatigue. This outcome assesses change in VAS-MF score from baseline to Week 4 and Week 8

    Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)

  4. Change in PROMIS Fatigue Score

    The PROMIS Fatigue Short Form assesses self-reported fatigue and its interference with daily functioning. Scores are reported as standardized T-scores (mean 50, SD 10); higher scores indicate greater fatigue. This outcome measures change in PROMIS Fatigue from baseline to Week 4 and Week 8.

    Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)

  5. Change in Neuro-QoL Fatigue

    Neuro-QoL Fatigue evaluates the impact of fatigue on quality of life in neurological conditions. Scores are converted to T-scores (mean 50, SD 10), with higher scores indicating worse fatigue-related QoL. This outcome measures change in Neuro-QoL Fatigue from baseline to Week 4 and Week 8

    Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)

  6. Change in Symbol Digit Modalities Test (SDMT)

    The SDMT is a widely used measure of information processing speed. The score reflects the number of correct symbol-digit matches completed in 90 seconds, with higher scores indicating better cognitive performance. This outcome assesses change in SDMT score from baseline to Week 4 and Week 8.

    Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)

  7. Rate of Change in Daily Fatigue Severity (DFS) During the Treatment Period

    Daily Fatigue Severity (DFS) is assessed using a repeated self-reported rating of fatigue severity. Participants respond to the question "How fatigued do you feel today?" using a 7-point Likert scale, where higher scores indicate greater fatigue. This outcome assesses the rate of change in DFS across the treatment period to characterize longitudinal changes in daily fatigue.

    Time frame: Baseline through End of treatment (week 4)

Other outcomes

  1. Change in MFIS Subscale Scores (Physical, Cognitive, Psychosocial)

    The MFIS yields three subscale scores assessing physical, cognitive, and psychosocial fatigue impact. Higher scores indicate greater impairment. This outcome measures change in each subscale from baseline to Week 4 and Week 8.

    Time frame: Baseline to End of Treatment (week 4) and Follow-up (week 8)

  2. Cognitive Performance During Stimulation (Embedded Virtual Reality Tasks)

    Cognitive performance is assessed using tasks embedded within the virtual reality environment during stimulation sessions. These tasks are designed to probe attention, processing speed, and learning dynamics while participants receive either active or sham stimulation. Performance data collected across sessions will be used for exploratory analyses of cognitive performance and learning trajectories during the treatment period.

    Time frame: Baseline through End of Treatment (week 4)

  3. Treatment Acceptability Ratings

    Longitudinal acceptability is evaluated at Weeks 2, 4 and 8 by asking participants about their willingness to use the device at home as a future treatment for MS-related fatigue. Responses provide insight into perceived usability, tolerability, and overall acceptability of the intervention over time.

    Time frame: Week 2, Week 4, and Week 8

  4. Incidence of Adverse Events (AEs)

    AEs are defined as any unfavorable medical occurrence during the study, whether or not considered related to the intervention. Events are categorized by severity and relationship to study treatment. This outcome measures the proportion of participants experiencing at least one AE.

    Time frame: Baseline through Follow-up (week 8)

  5. Incidence of Serious Adverse Events (SAEs)

    SAEs include events resulting in hospitalization, persistent disability, life-threatening conditions, or death. This outcome reports the number and proportion of participants experiencing SAEs during the study.

    Time frame: Baseline through Week 8

  6. Tolerability: Session Attendance / Adherence Rate

    Tolerability is assessed through adherence to the prescribed stimulation schedule. This outcome measures the percentage of completed sessions out of the total required (16 sessions delivered over 4 weeks).

    Time frame: Weeks 0-4

  7. Study Retention Rate

    Retention rate is defined as the proportion of participants who complete the follow-up assessment (week 8) relative to those enrolled.

    Time frame: Baseline through Follow-up (week 8)

  8. Events of Clinical Interest (Agitation/Confusion)

    Events of clinical interest include agitation, confusion, or disorientation occurring within 1 hour of stimulation. This outcome captures their incidence and severity.

    Time frame: Immediately monitored following stimulation; Through Week 4

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Reis C, Azizollahi H, Headley G, Navarro S, Hanslmayr S, Clouter A, Zanto TP, Certain R. VR-based gamma sensory stimulation: a pilot feasibility study. Sci Rep. 2025 Aug 5;15(1):28491. doi: 10.1038/s41598-025-13725-6. PubMed 40764732 ↗
  • Adaikkan C, Tsai LH. Gamma Entrainment: Impact on Neurocircuits, Glia, and Therapeutic Opportunities. Trends Neurosci. 2020 Jan;43(1):24-41. doi: 10.1016/j.tins.2019.11.001. Epub 2019 Dec 10. PubMed 31836315 ↗
  • Rodrigues-Amorim D, Bozzelli PL, Kim T, Liu L, Gibson O, Yang CY, Murdock MH, Galiana-Melendez F, Schatz B, Davison A, Islam MR, Shin Park D, Raju RM, Abdurrob F, Nelson AJ, Min Ren J, Yang V, Stokes MP, Tsai LH. Multisensory gamma stimulation mitigates the effects of demyelination induced by cuprizone in male mice. Nat Commun. 2024 Aug 8;15(1):6744. doi: 10.1038/s41467-024-51003-7. PubMed 39112447 ↗

Individual participant data

Plan to share: No — This study collects pseudonymized clinical, behavioral, and EEG data that are subject to GDPR and local data protection regulations. Because the dataset contains sensitive information that cannot be fully de-identified, individual-level data will not be made publicly available. Aggregate results may be shared in publications or upon reasonable request to the sponsor.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.

Of 874 interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 10 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Mar 2026 → Aug 2026, primary completion Mar 2027 → Jun 2027 and completion Apr 2027 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Aug 3, 2026was Mar 2026
Primary completionEst.
Jun 30, 2027was Mar 2027
CompletionEst.
Aug 31, 2027was Apr 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
Hospital del Mar is now Recruiting
Oct 22, 2026
Start date
Mar 1, 2026→Aug 3, 2026 (actual)
Oct 22, 2026
Primary completion
Mar 1, 2027→Jun 30, 2027
Oct 22, 2026
Study completion
Apr 1, 2027→Aug 31, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    Hospital del Mar is now Recruiting
    Start date Mar 1, 2026→Aug 3, 2026 (now actual)
    Primary completion Mar 1, 2027→Jun 30, 2027
    Study completion Apr 1, 2027→Aug 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07310862
Lead sponsor
Clarity Health Technologies, Inc
Collaborators
Parc de Salut Mar
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Aug 3, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Carolina Reis, PhD
Contact
carolina@clarity-technologies.com
+33781261622
Sergi Navarro, MSc
Contact
sergi@clarity-technologies.com
+34629116058

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion